Regeneron and Novo Nordisk Combination Therapy Reduces Muscle Loss in Study
An experimental drug developed by Regeneron, when used alongside Novo Nordisk's semaglutide, reduced muscle loss by half compared to using semaglutide alone. The study focused on patients with obesity or related conditions and highlights the potential for combination therapies to mitigate a common side effect of weight-loss drugs. This development could influence how GLP-1 receptor agonists are used in clinical settings, as preserving lean body mass is an important consideration during significant weight loss. Regeneron's drug appears to complement Novo Nordisk’s widely prescribed semaglutide by addressing muscle preservation concerns. The results may encourage further research into combination therapies and could impact the broader GLP-1 market dynamics.
Topics: muscle mass preservation Novo Nordisk Regeneron semaglutide weight-loss drug